title: Apathy and associated factors in Mexican patients with Parkinson's disease.
abstract: Apathy is one of the most common behavioral disturbances in Parkinson's disease (PD) with a reported prevalence of 17-51 %. Apathy has been associated with depression, cognitive deficits, and poor quality of life. The objective of this study was to determine the prevalence of apathy in Mexican subjects with PD and its correlation with clinical and demographic characteristics. A cross-sectional, descriptive, and analytic study was carried out. Consecutive subjects with PD attending the National Institute of Neurology and Neurosurgery in Mexico City were included. Demographic and other relevant clinical data were collected. The Apathy Scale was applied to all subjects. A cut-off score of ≥ 14 was used. A total of 241 non-demented patients (52.7 % male) were included. Apathy was found in 43 % of subjects. Lower body mass index, older age of PD onset, cognitive decline and disease severity were all related to apathy. The use of dopamine agonists or rasagiline was more common in patients with low apathy scores. Our results show that the prevalence of apathy in Mexican subjects with PD is similar to other reports.
authors.affiliation: Clinical Laboratory of Neurodegenerative Diseases, National Institute of Neurology and Neurosurgery, Insurgentes Sur #3877 Col. La Fama, 14269, Mexico City, Mexico, mrodriguez@innn.edu.mx.
authors.forename: Mayela
authors.initials: M
authors.lastname: Rodríguez-Violante
authors.forename: Paulina
authors.initials: P
authors.lastname: González-Latapi
authors.forename: Amin
authors.initials: A
authors.lastname: Cervantes-Arriaga
authors.forename: Daniel
authors.initials: D
authors.lastname: Martínez-Ramírez
authors.forename: Salvador
authors.initials: S
authors.lastname: Velázquez-Osuna
authors.forename: Azyadeh
authors.initials: A
authors.lastname: Camacho-Ordoñez
mesh_terms: D017668:Age of Onset; D000978:Antiparkinson Agents / Q000627:therapeutic use; D057565:Apathy; D015992:Body Mass Index; D003430:Cross-Sectional Studies; D018491:Dopamine Agonists / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007189:Indans / Q000627:therapeutic use; D008297:Male; D008800:Mexico / Q000453:epidemiology; D008875:Middle Aged; D010300:Parkinson Disease / Q000188:drug therapy / Q000453:epidemiology* / Q000523:psychology*; D015995:Prevalence; D011569:Psychiatric Status Rating Scales; D012720:Severity of Illness Index
chemical_list: D000978:Antiparkinson Agents; D018491:Dopamine Agonists; D007189:Indans; C031967:rasagiline